Earnings Releases·Nov 5, 2026, 7:35 AM ET

Dyne Therapeutics — Third Quarter 2026 Earnings Summary

Net loss widened to $193.6 million ($1.06 per share) for Q3 2026 from $108.0 million ($0.76 per share) in the prior year period, driven by a 77% increase in R&D expenses to $161.7 million and a 111% rise in G&A expenses to $35.3 million.
Cash and marketable securities increased to $1.134 billion as of September 30, 2026, providing sufficient liquidity to fund operations through Q2 2028.
z-rostudirsen BLA is under FDA priority review with a PDUFA date of January 21, 2027, while z-basivarsen Phase 3 HARMONIA trial enrollment continues; both programs target potential U.S. launches in 2027 and 2028, respectively, pending regulatory approval.
Management is expanding headcount and manufacturing capacity to prepare for the potential commercial launch of z-rostudirsen, while advancing four additional preclinical DMD exon-skipping programs.